{"id":350612,"date":"2025-08-25T19:52:22","date_gmt":"2025-08-25T19:52:22","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-ascendis-pharma-as\/"},"modified":"2025-08-25T19:52:22","modified_gmt":"2025-08-25T19:52:22","slug":"how-to-buy-ascendis-pharma-as","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/","title":{"rendered":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-350612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Ascendis Pharma A\/S (ASND) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Ascendis Pharma A\/S (ASND) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin."},"intro":"B\u00fcy\u00fcyen biyoteknoloji sekt\u00f6r\u00fcne girmeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ascendis Pharma A\/S (ASND), nadir hastal\u0131k tedavilerinde en heyecan verici b\u00fcy\u00fcme hikayelerinden birini temsil ediyor. Devrim niteli\u011findeki TransCon teknoloji platformlar\u0131 ve patlay\u0131c\u0131 gelir art\u0131\u015f\u0131 ile bu Danimarkal\u0131 yenilik\u00e7i, size \u00f6nemli getiriler sa\u011flayabilir. Bu ila\u00e7 devi \u015firkete yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u00fcy\u00fcyen biyoteknoloji sekt\u00f6r\u00fcne girmeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ascendis Pharma A\/S (ASND), nadir hastal\u0131k tedavilerinde en heyecan verici b\u00fcy\u00fcme hikayelerinden birini temsil ediyor. Devrim niteli\u011findeki TransCon teknoloji platformlar\u0131 ve patlay\u0131c\u0131 gelir art\u0131\u015f\u0131 ile bu Danimarkal\u0131 yenilik\u00e7i, size \u00f6nemli getiriler sa\u011flayabilir. Bu ila\u00e7 devi \u015firkete yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim."},"body_html":"<h2>\ud83d\udcc8 Ascendis Pharma Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Ascendis Pharma A\/S (ASND), NASDAQ'ta <strong>194,30 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>13 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporu a\u00e7\u0131klanacak. Ancak as\u0131l d\u00f6n\u00fcm noktas\u0131 bundan hemen \u00f6nce geliyor...<\/p> <p><strong>30 Kas\u0131m 2025<\/strong>, TransCon CNP onay\u0131 i\u00e7in FDA'n\u0131n PDUFA tarihidir. Bu tek karar, hissenin \u00f6n\u00fcm\u00fczdeki y\u0131lki seyrini belirleyebilir. Tarihsel olarak, Ascendis \u00fcr\u00fcnleriyle ilgili FDA kararlar\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131na yol a\u00e7m\u0131\u015ft\u0131r.<\/p> <h3>FDA Kararlar\u0131n\u0131n ASND Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/h3> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>A\u011fu 2024<\/td><td>YORVIPATH Onay\u0131<\/td><td>145 $<\/td><td>%28 Art\u0131\u015f (1 hafta)<\/td><\/tr> <tr><td>Mar 2025<\/td><td>SKYTROFA Geni\u015flemesi<\/td><td>168 $<\/td><td>%15 Art\u0131\u015f (3 g\u00fcn)<\/td><\/tr> <tr><td>Oca 2025<\/td><td>Klinik Deneme Sonu\u00e7lar\u0131<\/td><td>132 $<\/td><td>%12 D\u00fc\u015f\u00fc\u015f (hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan veriler)<\/td><\/tr> <\/tbody> <\/table> <p>Desen a\u00e7\u0131k: olumlu d\u00fczenleyici haberler \u00e7ift haneli kazan\u00e7lar sa\u011flarken, aksilikler \u00f6nemli d\u00fczeltmelere neden oluyor. Kas\u0131m karar\u0131 2025'in en b\u00fcy\u00fck kataliz\u00f6r\u00fc olacak.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h3> <p>ASND hisseleri bu d\u00f6nemde etkileyici bir <strong>%75 art\u0131\u015f<\/strong> g\u00f6sterdi:<\/p> <ul> <li><strong>\u015eubat<\/strong>: 111,09 $ (52 haftan\u0131n en d\u00fc\u015f\u00fck seviyesi, piyasa belirsizli\u011fi)<\/li> <li><strong>Nisan<\/strong>: 150,12 $ (200 g\u00fcnl\u00fck hareketli ortalamay\u0131 k\u0131rd\u0131)<\/li> <li><strong>Haziran<\/strong>: 188,79 $ (t\u00fcm zamanlar\u0131n en y\u00fcksek seviyelerine yakla\u015f\u0131yor)<\/li> <li><strong>A\u011fustos<\/strong>: 194,30 $ (zirve seviyelerine yak\u0131n konsolidasyon)<\/li> <\/ul> <p>Bu dramatik y\u00fckseli\u015fin sebebi? \u00dc\u00e7 kelime: <strong>patlay\u0131c\u0131 gelir art\u0131\u015f\u0131<\/strong>. \u015eirketin 2025 2. \u00e7eyrek sonu\u00e7lar\u0131, YORVIPATH ve SKYTROFA'n\u0131n ba\u015far\u0131l\u0131 lansmanlar\u0131yla desteklenen %339'luk muazzam bir <strong>gelir art\u0131\u015f\u0131<\/strong> ile 158 milyon \u20ac'ya ula\u015ft\u0131.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 220-240 $ (FDA onay\u0131 bekleniyor) \u2192 <strong>ONAYLANIRSA G\u00dc\u00c7L\u00dc AL<\/strong><\/li> <li><strong>2026<\/strong>: 260-300 $ (TransCon CNP'nin tam ticarile\u015fmesi)<\/li> <li><strong>2028<\/strong>: 380-450 $ (pipeline geni\u015flemesi ve uluslararas\u0131 b\u00fcy\u00fcme)<\/li> <li><strong>2030<\/strong>: 550-650 $ (endokrin nadir hastal\u0131klarda pazar liderli\u011fi)<\/li> <\/ul> <p>Karar? Bu, biyoteknoloji volatilitesine dayanabilen yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>y\u00fcksek risk, y\u00fcksek getiri f\u0131rsat\u0131<\/strong>. Kas\u0131m FDA karar\u0131 her \u015fey demek\u2014onay, bu hisseyi y\u00f6r\u00fcngeye f\u0131rlatabilir.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA reddi riski<\/strong>: TransCon CNP onaylanmazsa %20-30 potansiyel d\u00fc\u015f\u00fc\u015f<\/li> <li><strong>Mali zararlar<\/strong>: B\u00fcy\u00fck gelir art\u0131\u015f\u0131na ra\u011fmen 38,9 milyon \u20ac net zarar<\/li> <li><strong>Y\u00fcksek volatilite<\/strong>: %40,1 y\u0131ll\u0131k volatilite, vah\u015fi fiyat dalgalanmalar\u0131 demek<\/li> <li><strong>Rekabet bask\u0131s\u0131<\/strong>: Pfizer ve Novo Nordisk pazarlar\u0131n\u0131 ku\u015fat\u0131yor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Gelir patlamas\u0131<\/strong>: %339 b\u00fcy\u00fcme yaz\u0131m hatas\u0131 de\u011fil\u2014ger\u00e7ek<\/li> <li><strong>Pazar geni\u015flemesi<\/strong>: YORVIPATH art\u0131k d\u00fcnya \u00e7ap\u0131nda 75+ \u00fclkede<\/li> <li><strong>Nakit rezervleri<\/strong>: Operasyonlar i\u00e7in 494 milyon \u20ac sava\u015f kasas\u0131<\/li> <li><strong>Analist deste\u011fi<\/strong>: 16 analistin tamam\u0131 Al veya G\u00fc\u00e7l\u00fc Al diyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Kas\u0131m\u0131 bekleyin<\/strong>: FDA karar\u0131 \u00e7ok b\u00fcy\u00fck\u2014haber sonras\u0131 pozisyon al\u0131n<\/li> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fc ile dolar maliyeti ortalamas\u0131 yap\u0131n<\/li> <li><strong>Stop-loss koyun<\/strong>: 175 $ (30 g\u00fcnl\u00fck destek) ve 150 $ (200 g\u00fcnl\u00fck MA) seviyelerinde<\/li> <li><strong>Kazan\u00e7lar\u0131 takip edin<\/strong>: 13 Kas\u0131m'daki 3. \u00e7eyrek raporu ticari ilerlemeyi g\u00f6sterecek<\/li> <\/ol> <p>Espiri: \"ASND ile i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece \u00f6d\u00fcllendirici ama dramatik ruh hali de\u011fi\u015fimlerine a\u00e7\u0131k. Duygusal dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131z\u0131 ve g\u00fc\u00e7l\u00fc bir mideyi yan\u0131n\u0131zda getirin!\"<\/p> <h2>\u2705 Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve par\u00e7al\u0131 hisse sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Kaybetmeye raz\u0131 oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"ASND\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmamak i\u00e7in limit emirleri tercih edin<\/td><\/tr> <tr><td>5<\/td><td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td><td>\u00dccretleri kontrol edin\u2014toplam komisyon %1'in alt\u0131nda olsun<\/td><\/tr> <\/tbody> <\/table> <h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Uygun?<\/h3> <p>Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p> <ul> <li><strong>5 $ minimum depozito<\/strong>\u2014ger\u00e7ek para ile stratejileri test edin, b\u00fct\u00e7enizi zorlamadan<\/li> <li><strong>1 dakikal\u0131k do\u011frulama<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto, e-c\u00fczdanlar, banka kartlar\u0131 ile esneklik<\/li> <li><strong>Par\u00e7al\u0131 hisseler<\/strong>\u2014ASND gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Ascendis Pharma: TransCon Devrimi<\/h2> <p>Ascendis Pharma sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014endokrin nadir hastal\u0131k tedavisinde gelece\u011fi \u015fekillendiriyor. TransCon teknoloji platformlar\u0131, daha az enjeksiyonla s\u00fcrekli ila\u00e7 sal\u0131n\u0131m\u0131 sa\u011flayan ger\u00e7ek bir at\u0131l\u0131m temsil ediyor.<\/p> <p>\u015eirket \u015fu anda b\u00fcy\u00fcme hormonu bozukluklar\u0131 ve hipoparatiroidizm tedavileri i\u00e7in b\u00fcy\u00fcyen pazarda lider konumda. YORVIPATH, 2025 ortalar\u0131na kadar 3.100'den fazla hasta re\u00e7etesi al\u0131rken, SKYTROFA yeti\u015fkin pazarlara geni\u015fliyor ve ticari motor tam gaz \u00e7al\u0131\u015f\u0131yor.<\/p> <p><strong>2025 E\u011flenceli Ger\u00e7ek<\/strong>: Ascendis Pharma'n\u0131n Kopenhag merkezinde, \u00e7al\u0131\u015fanlar\u0131n TransCon bile\u015fiklerinin dev modelleri aras\u0131nda y\u00fcr\u00fcyebildi\u011fi bir \"molek\u00fcl heykel bah\u00e7esi\" bulunuyor. Bilim insanlar\u0131 \u00f6\u011fle molalar\u0131nda yeniliklerinin aras\u0131nda adeta geziniyor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Ascendis Pharma Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Ascendis Pharma A\/S (ASND), NASDAQ&#8217;ta <strong>194,30 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>13 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporu a\u00e7\u0131klanacak. Ancak as\u0131l d\u00f6n\u00fcm noktas\u0131 bundan hemen \u00f6nce geliyor&#8230;<\/p>\n<p><strong>30 Kas\u0131m 2025<\/strong>, TransCon CNP onay\u0131 i\u00e7in FDA&#8217;n\u0131n PDUFA tarihidir. Bu tek karar, hissenin \u00f6n\u00fcm\u00fczdeki y\u0131lki seyrini belirleyebilir. Tarihsel olarak, Ascendis \u00fcr\u00fcnleriyle ilgili FDA kararlar\u0131 b\u00fcy\u00fck fiyat dalgalanmalar\u0131na yol a\u00e7m\u0131\u015ft\u0131r.<\/p>\n<h3>FDA Kararlar\u0131n\u0131n ASND Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/h3>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>YORVIPATH Onay\u0131<\/td>\n<td>145 $<\/td>\n<td>%28 Art\u0131\u015f (1 hafta)<\/td>\n<\/tr>\n<tr>\n<td>Mar 2025<\/td>\n<td>SKYTROFA Geni\u015flemesi<\/td>\n<td>168 $<\/td>\n<td>%15 Art\u0131\u015f (3 g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>Oca 2025<\/td>\n<td>Klinik Deneme Sonu\u00e7lar\u0131<\/td>\n<td>132 $<\/td>\n<td>%12 D\u00fc\u015f\u00fc\u015f (hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan veriler)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen a\u00e7\u0131k: olumlu d\u00fczenleyici haberler \u00e7ift haneli kazan\u00e7lar sa\u011flarken, aksilikler \u00f6nemli d\u00fczeltmelere neden oluyor. Kas\u0131m karar\u0131 2025&#8217;in en b\u00fcy\u00fck kataliz\u00f6r\u00fc olacak.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h3>\n<p>ASND hisseleri bu d\u00f6nemde etkileyici bir <strong>%75 art\u0131\u015f<\/strong> g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: 111,09 $ (52 haftan\u0131n en d\u00fc\u015f\u00fck seviyesi, piyasa belirsizli\u011fi)<\/li>\n<li><strong>Nisan<\/strong>: 150,12 $ (200 g\u00fcnl\u00fck hareketli ortalamay\u0131 k\u0131rd\u0131)<\/li>\n<li><strong>Haziran<\/strong>: 188,79 $ (t\u00fcm zamanlar\u0131n en y\u00fcksek seviyelerine yakla\u015f\u0131yor)<\/li>\n<li><strong>A\u011fustos<\/strong>: 194,30 $ (zirve seviyelerine yak\u0131n konsolidasyon)<\/li>\n<\/ul>\n<p>Bu dramatik y\u00fckseli\u015fin sebebi? \u00dc\u00e7 kelime: <strong>patlay\u0131c\u0131 gelir art\u0131\u015f\u0131<\/strong>. \u015eirketin 2025 2. \u00e7eyrek sonu\u00e7lar\u0131, YORVIPATH ve SKYTROFA&#8217;n\u0131n ba\u015far\u0131l\u0131 lansmanlar\u0131yla desteklenen %339&#8217;luk muazzam bir <strong>gelir art\u0131\u015f\u0131<\/strong> ile 158 milyon \u20ac&#8217;ya ula\u015ft\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 220-240 $ (FDA onay\u0131 bekleniyor) \u2192 <strong>ONAYLANIRSA G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n<li><strong>2026<\/strong>: 260-300 $ (TransCon CNP&#8217;nin tam ticarile\u015fmesi)<\/li>\n<li><strong>2028<\/strong>: 380-450 $ (pipeline geni\u015flemesi ve uluslararas\u0131 b\u00fcy\u00fcme)<\/li>\n<li><strong>2030<\/strong>: 550-650 $ (endokrin nadir hastal\u0131klarda pazar liderli\u011fi)<\/li>\n<\/ul>\n<p>Karar? Bu, biyoteknoloji volatilitesine dayanabilen yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>y\u00fcksek risk, y\u00fcksek getiri f\u0131rsat\u0131<\/strong>. Kas\u0131m FDA karar\u0131 her \u015fey demek\u2014onay, bu hisseyi y\u00f6r\u00fcngeye f\u0131rlatabilir.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA reddi riski<\/strong>: TransCon CNP onaylanmazsa %20-30 potansiyel d\u00fc\u015f\u00fc\u015f<\/li>\n<li><strong>Mali zararlar<\/strong>: B\u00fcy\u00fck gelir art\u0131\u015f\u0131na ra\u011fmen 38,9 milyon \u20ac net zarar<\/li>\n<li><strong>Y\u00fcksek volatilite<\/strong>: %40,1 y\u0131ll\u0131k volatilite, vah\u015fi fiyat dalgalanmalar\u0131 demek<\/li>\n<li><strong>Rekabet bask\u0131s\u0131<\/strong>: Pfizer ve Novo Nordisk pazarlar\u0131n\u0131 ku\u015fat\u0131yor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Gelir patlamas\u0131<\/strong>: %339 b\u00fcy\u00fcme yaz\u0131m hatas\u0131 de\u011fil\u2014ger\u00e7ek<\/li>\n<li><strong>Pazar geni\u015flemesi<\/strong>: YORVIPATH art\u0131k d\u00fcnya \u00e7ap\u0131nda 75+ \u00fclkede<\/li>\n<li><strong>Nakit rezervleri<\/strong>: Operasyonlar i\u00e7in 494 milyon \u20ac sava\u015f kasas\u0131<\/li>\n<li><strong>Analist deste\u011fi<\/strong>: 16 analistin tamam\u0131 Al veya G\u00fc\u00e7l\u00fc Al diyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Kas\u0131m\u0131 bekleyin<\/strong>: FDA karar\u0131 \u00e7ok b\u00fcy\u00fck\u2014haber sonras\u0131 pozisyon al\u0131n<\/li>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fc ile dolar maliyeti ortalamas\u0131 yap\u0131n<\/li>\n<li><strong>Stop-loss koyun<\/strong>: 175 $ (30 g\u00fcnl\u00fck destek) ve 150 $ (200 g\u00fcnl\u00fck MA) seviyelerinde<\/li>\n<li><strong>Kazan\u00e7lar\u0131 takip edin<\/strong>: 13 Kas\u0131m&#8217;daki 3. \u00e7eyrek raporu ticari ilerlemeyi g\u00f6sterecek<\/li>\n<\/ol>\n<p>Espiri: &#8220;ASND ile i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece \u00f6d\u00fcllendirici ama dramatik ruh hali de\u011fi\u015fimlerine a\u00e7\u0131k. Duygusal dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131z\u0131 ve g\u00fc\u00e7l\u00fc bir mideyi yan\u0131n\u0131zda getirin!&#8221;<\/p>\n<h2>\u2705 Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve par\u00e7al\u0131 hisse sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Kaybetmeye raz\u0131 oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ASND&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmamak i\u00e7in limit emirleri tercih edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin<\/td>\n<td>\u00dccretleri kontrol edin\u2014toplam komisyon %1&#8217;in alt\u0131nda olsun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Uygun?<\/h3>\n<p>Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p>\n<ul>\n<li><strong>5 $ minimum depozito<\/strong>\u2014ger\u00e7ek para ile stratejileri test edin, b\u00fct\u00e7enizi zorlamadan<\/li>\n<li><strong>1 dakikal\u0131k do\u011frulama<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto, e-c\u00fczdanlar, banka kartlar\u0131 ile esneklik<\/li>\n<li><strong>Par\u00e7al\u0131 hisseler<\/strong>\u2014ASND gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Ascendis Pharma: TransCon Devrimi<\/h2>\n<p>Ascendis Pharma sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014endokrin nadir hastal\u0131k tedavisinde gelece\u011fi \u015fekillendiriyor. TransCon teknoloji platformlar\u0131, daha az enjeksiyonla s\u00fcrekli ila\u00e7 sal\u0131n\u0131m\u0131 sa\u011flayan ger\u00e7ek bir at\u0131l\u0131m temsil ediyor.<\/p>\n<p>\u015eirket \u015fu anda b\u00fcy\u00fcme hormonu bozukluklar\u0131 ve hipoparatiroidizm tedavileri i\u00e7in b\u00fcy\u00fcyen pazarda lider konumda. YORVIPATH, 2025 ortalar\u0131na kadar 3.100&#8217;den fazla hasta re\u00e7etesi al\u0131rken, SKYTROFA yeti\u015fkin pazarlara geni\u015fliyor ve ticari motor tam gaz \u00e7al\u0131\u015f\u0131yor.<\/p>\n<p><strong>2025 E\u011flenceli Ger\u00e7ek<\/strong>: Ascendis Pharma&#8217;n\u0131n Kopenhag merkezinde, \u00e7al\u0131\u015fanlar\u0131n TransCon bile\u015fiklerinin dev modelleri aras\u0131nda y\u00fcr\u00fcyebildi\u011fi bir &#8220;molek\u00fcl heykel bah\u00e7esi&#8221; bulunuyor. Bilim insanlar\u0131 \u00f6\u011fle molalar\u0131nda yeniliklerinin aras\u0131nda adeta geziniyor!<\/p>\n"},"faq":[{"question":"Ascendis Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ASND\" sembol\u00fc ile arama yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in ve sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin."},{"question":"FDA onay\u0131n\u0131n Ascendis Pharma hisseleri \u00fczerindeki etkisi nedir?","answer":"FDA onaylar\u0131 genellikle hissede \u00e7ift haneli art\u0131\u015flara yol a\u00e7arken, reddedilme durumunda \u00f6nemli fiyat d\u00fc\u015f\u00fc\u015fleri ya\u015fanabilir."},{"question":"Ascendis Pharma'n\u0131n 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 220-240 $, 2026'da 260-300 $, 2028'de 380-450 $ ve 2030'da 550-650 $ aral\u0131\u011f\u0131nda fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"FDA reddi riski, mali zararlar, y\u00fcksek volatilite ve rekabet bask\u0131s\u0131 \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyesi nedir?","answer":"Kas\u0131m FDA karar\u0131n\u0131 beklemek, k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak, stop-loss seviyeleri belirlemek ve kazan\u00e7 raporlar\u0131n\u0131 takip etmek \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Ascendis Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ASND\" sembol\u00fc ile arama yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in ve sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin."},{"question":"FDA onay\u0131n\u0131n Ascendis Pharma hisseleri \u00fczerindeki etkisi nedir?","answer":"FDA onaylar\u0131 genellikle hissede \u00e7ift haneli art\u0131\u015flara yol a\u00e7arken, reddedilme durumunda \u00f6nemli fiyat d\u00fc\u015f\u00fc\u015fleri ya\u015fanabilir."},{"question":"Ascendis Pharma'n\u0131n 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 220-240 $, 2026'da 260-300 $, 2028'de 380-450 $ ve 2030'da 550-650 $ aral\u0131\u011f\u0131nda fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"FDA reddi riski, mali zararlar, y\u00fcksek volatilite ve rekabet bask\u0131s\u0131 \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyesi nedir?","answer":"Kas\u0131m FDA karar\u0131n\u0131 beklemek, k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak, stop-loss seviyeleri belirlemek ve kazan\u00e7 raporlar\u0131n\u0131 takip etmek \u00f6nerilir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T19:52:22+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T19:52:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\",\"name\":\"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-25T19:52:22+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/","og_locale":"tr_TR","og_type":"article","og_title":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T19:52:22+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T19:52:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/","name":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-25T19:52:22+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma A\/S (ASND) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ascendis Pharma A\/S (ASND) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":350609,"slug":"how-to-buy-ascendis-pharma-as","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Ascendis Pharma A\/S (ASND) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Ascendis Pharma A\/S (ASND)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/"},"pt_AA":{"locale":"pt_AA","id":350610,"slug":"how-to-buy-ascendis-pharma-as","post_title":"Como comprar a\u00e7\u00f5es da Ascendis Pharma A\/S (ASND) - Investimento em a\u00e7\u00f5es da Ascendis Pharma A\/S (ASND)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ascendis-pharma-as\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=350612"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350612\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=350612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=350612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=350612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}